Vismodegib, an SMO inhibitor, was approved by the United States Food and Drug Administration (FDA) in January 2012 for the treatment of symptomatic metastatic basal cell carcinoma (BBC) and locally advanced BBC in adult patients [38]. The gene discussed is SMO; the disease is basal cell carcinoma.